Efficacy

Zynlonta (loncastuximab tesirine-lpyl) for Lymphoma

Zynlonta (loncastuximab tesirine-lpyl) is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), DLBCL arising from low grade lymphoma, and also high-grade B-cell lymphoma. The efficacy of Zynlonta was evaluated in a multicenter, single-arm, open-label clinical trial, where a significant proportion of patients achieved an objective response rate (ORR), which is a combined measure of complete and partial responses to the treatment.

During the clinical trial, the complete response (CR) rate was a key indicator of Zynlonta's efficacy. Patients who achieved CR showed a disappearance of all signs of cancer, which is a strong positive outcome for those with relapsed or refractory large B-cell lymphoma. The duration of response (DOR) for these patients was also an important measure, indicating how long the patients maintained their response to the treatment without disease progression.

Lunsumio (mosunetuzumab-axgb) for Lymphoma

Lunsumio (mosunetuzumab-axgb) is a bispecific CD20-directed and CD3-directed cytolytic antibody indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Mosunetuzumab-axgb is designed to engage both CD20 on B-cells and CD3 on T-cells, thereby redirecting T-cells to engage and eliminate B-cell lymphoma. The efficacy of Lunsumio was demonstrated in a pivotal phase I/II study, where it showed a notable ORR in patients with heavily pretreated follicular lymphoma.

The efficacy of Lunsumio is further illustrated by its CR rate, which reflects the percentage of patients who achieved the complete disappearance of all detectable cancer. The DOR in responding patients is also a critical aspect of its efficacy profile, indicating the sustainability of the response over time. Additionally, the safety and tolerability profile of Lunsumio supports its use in the indicated patient population, with a management strategy for the cytokine release syndrome (CRS) and neurologic toxicities that are known risks with T-cell engaging therapies.